Shorted

Algorae Pharmaceuticals (1AI) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Algorae Pharmaceuticals Announces Forfeiture of 35 Million Performance Rights After Conditions Not Met

Algorae Pharmaceuticals Limited (ASX: 1AI) has confirmed the forfeiture of 35 million performance rights due to unmet or unsatisfiable conditions. These unquoted securities ceased on 14 July 2026 after the stipulated conditions lapsed. Post-cessation, the company retains 179 million performance rights alongside 2.03 billion ordinary shares issued. Key Points Algorae Pharmaceuticals Limited (1AI), an ASX-listed pharmaceutical company, forfeited 35 million performance rights after conditions we...

Continue reading
Kalkine
Neutral
just now

Algorae Pharmaceuticals Announces Bradley Dilkes' Departure with Final Director Interest Disclosure

Algorae Pharmaceuticals Limited (ASX: 1AI) has submitted a Final Director's Interest Notice confirming that Bradley John Dilkes ended his directorship on 14 July 2026. The filing details Dilkes' shareholding at departure, including both direct and indirect holdings in the company's fully paid ordinary shares. This regulatory document officially marks the end of Dilkes' tenure and provides investors with a comprehensive record of his securities ownership as of his exit date. Key Points Algorae...

Continue reading
Kalkine
Neutral
just now

Algorae Pharmaceuticals (ASX:1AI) Rises as Cash Burn Eases

Highlights Cash management remains central to early-stage pharmaceutical development Reduced cash outflow reflects tighter operational control Market attention highlights funding capacity and sustainability Algorae Pharmaceuticals trends within all ordinaries show controlled cash usage, funding considerations, and biotechnology sector movement as development progresses without established revenue streams. The pharmaceutical and biotechnology sector forms a dynamic segment within the all ordin...

Continue reading
Kalkine
Neutral
just now

Algorae Pharmaceuticals (ASX:1AI) Trends in the All Ordinaries

Highlights Operations focused on pharmaceutical development and early-stage research Cash management showing steady adjustments despite limited revenue Monitored within broader market metrics including the all ordinaries Algorae Pharmaceuticals (ASX:1AI) emphasizes research, cash oversight, and sector positioning, contextualized by movements in the all ordinaries chart and broader ASX developments. Algorae Pharmaceuticals operates within the biotechnology and pharmaceutical sector, concentrat...

Continue reading
Kalkine
Neutral
just now

Is Algorae Pharma (ASX:1AI) shaping All Ords biotech focus?

Highlights Algorae Pharmaceuticals reflects activity within the biotechnology sector. Healthcare companies continue to advance research and development initiatives. Broader indices capture participation across emerging biotech firms. Algorae Pharmaceuticals highlights biotech sector activity within All Ordinaries, reflecting research-driven development and healthcare innovation in Australian markets. The biotechnology and pharmaceutical sector represents a specialised segment of the Aus...

Continue reading